Investigate the Relationship Between Inflammatory and Coagulation in SAH CSF
Inhibition of Caspase-1 Reduces Pyroptotic Neuroinflammation and Tissue Factor-Induced Cerebrospinal Fluid Circulation Impairment After Subarachnoid Hemorrhage
1 other identifier
observational
40
1 country
1
Brief Summary
Investigate the role of inflammasome and blood coagulation response in human cerebrospinal fluid after subarachnoid hemorrhage.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Dec 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2020
CompletedFirst Submitted
Initial submission to the registry
June 21, 2021
CompletedFirst Posted
Study publicly available on registry
June 24, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2021
CompletedJanuary 6, 2022
June 1, 2021
8 months
June 21, 2021
December 15, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Length of hospital stay
Length of hospital stay
evaluated 1day after discharge
modified Rankin Scale
modified Rankin Scale (mRS) at discharge. mRS ranging from 0-5, higher represents worse
evaluated 1day after discharge
Glasgow Outcome Scale
Glasgow Outcome Scale (GOS) at discharge, GOS ranging from 0-5, higher represents better
evaluated 1day after discharge
Study Arms (2)
subarachnoid hemorrhage
Patients with subarachnoid hemorrhage
Control
patients with non-neurological diseases
Interventions
Lumbar puncture to obtain the cerebrospinal fluid and for diagnostic test
Eligibility Criteria
Patients with SAH
You may qualify if:
- SAH patients with modified Fisher Scale 3-4.
You may not qualify if:
- Patients with history of CNS disease (e.g., stroke, traumatic brain injury, CNS infection) or accompanied by serious comorbidities before SAH onset (e.g., severe coagulation disorders, malignant tumor, uncontrollable heart disease, and hypertension) or other organ dysfunctions within 6 months were excluded from the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Second affiliated hosipital of zhejiang univerisity school of medicine
Hangzhou, Zhejiang, 310000, China
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Yuanjian Fang, M.D
Zhejiang Univerisity
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 21, 2021
First Posted
June 24, 2021
Study Start
December 1, 2020
Primary Completion
August 1, 2021
Study Completion
October 1, 2021
Last Updated
January 6, 2022
Record last verified: 2021-06
Data Sharing
- IPD Sharing
- Will not share